Artificial Intelligence: A New Era in Drug Discovery

Authors

  • Devendra Kumar Mishra Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.
  • Himani Awasthi Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

DOI:

https://doi.org/10.22270/ajprd.v9i5.995

Keywords:

Artificial intelligence, drug discovery, biopharmaceutical, clinical phase.

Abstract

Artificial intelligence (AI) is a simulation of the process of human intelligence through computers. The process involves obtaining information, developing rules for using information, making possible or accurate conclusions, and self-correcting. The development of new drug residues begins when basic scientists learn about biological targets (receptor, enzyme, protein, and gene). These targets involve the biological processes that occur in patients with a disease. Drug discovery can be through target identification, target verification, lead identification, and effectiveness of lead. AI can offer revolutionary insights into medicine, through data from genetics, proteomics and other life sciences that advance the process of discovery and development. Artificial Intelligence (AI) has recently been developed as a fiery element in the medical care industry. AI has exciting potential for prosperity in the field of biopharmaceutical. The biopharmaceutical industry makes efforts to approach AI to improve drug discovery, reduce research and development costs, reduce the time and cost of early drug discovery, and support predicting potential risks/side effects in late trials that can be very useful in avoiding traumatic events in clinical trials and ultimately clinical trials. Usually, drug development takes five years to go to trial, but the AI drug takes just 12 months. The rapid growth in life sciences and machine learning algorithms has led to enormous statistical access to the growth of AI-based startups focused on drug innovation in recent years.

 

 

Downloads

Download data is not yet available.

Author Biographies

Devendra Kumar Mishra, Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

Himani Awasthi, Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

Amity Institute of Pharmacy Lucknow, Amity University Uttar Pradesh, Sector 125, Noida, 201313, India.

 

References

1. McCarthy J, Hayes PJ. Some Philosophical Problems from the Standpoint of Artificial Intelligence. Readings in Artificial Intelligence. 1981:431-50.
2. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019;24(3):773-80.
3. Duch W, Swaminathan K, Meller J. Artificial Intelligence Approaches for Rational Drug Design and Discovery. Current Pharmaceutical Design. 2007;13:1497-508.
4. Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Elsevier Inc, Alzheimer’s & Dementia: Translational Research & Clinical Interventions. 2017;3(4):651-7.
5. Laghaee A, Malcolm C, Hallam J, Ghazal P. Artificial intelligence and robotics in high throughput post-genomics. Drug Discovery Today. 2005;10(18):1253-9.
6. Gawehn E, Hiss JA, Schneider G. Deep Learning in Drug Discovery. Molecular Informatic. 2016;35(1):3-14.
7. Agrawal P. Artificial Intelligence in Drug Discovery and Development. Artificial Intelligence in Drug Discovery and Development. 2018;6(2):1-2.
8. Chan HCS, Shan H, Dahoun T, Vogel H, Yuan S. Advancing Drug Discovery via Artificial Intelligence. Trends in Pharmacological Sciences. 2019;40(8):592-604.
9. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nature Review Drug Discovery. 2004;3(5):417-29.
10. Segler MHS, Kogej T, Tyrchan C, Waller MP. Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks. ACS Central Science. 2018;4(1):120-31.
11. Merk D, Friedrich L, Grisoni F, Schneider G. De Novo Design of Bioactive Small Molecules by Artificial Intelligence. Molecular Informatics. 2018;37(1-2).
12. Lake F. Artificial intelligence in drug discovery: what is new, and what is next? Future Drug Discovery. 2019;1(2):1-4.
13. Katsila T, Spyroulias GA, Patrinos GP, Matsoukas MT. Computational approaches in target identification and drug discovery. Computational and Structural Biotechnology Journal. 2016;14:177-84.
14. Menden MP, Iorio F, Garnett M, McDermott U, Benes CH, Ballester PJ, et al. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties. PLoS One. 2013;8(4):1-7.
15. Matthews H, Hanison J, Nirmalan N. "Omics"-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives. Proteomes. 2016;4(3):1-12.
16. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. British Journal of Pharmacology. 2011;162(6):1239-49.
17. Emig D, Ivliev A, Pustovalova O, Lancashire L, Bureeva S, Nikolsky Y, et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One. 2013;8(4):1-17.
18. Wang Q, Feng Y, Huang J, Wang T, Cheng G. A novel framework for the identification of drug target proteins: Combining stacked auto-encoders with a biased support vector machine. PLoS One. 2017;12(4):1-18.
19. Spencer M, Eickholt J, Jianlin C. A Deep Learning Network Approach to ab initio Protein Secondary Structure Prediction. IEEE/ACM Trans Comput Biol Bioinform. 2015;12(1):103-12.
20. Li H, Hou J, Adhikari B, Lyu Q, Cheng J. Deep learning methods for protein torsion angle prediction. BMC Bioinformatics. 2017;18(1):1-13.
21. Wang W, Yang S, Zhang X, Li J. Drug Repositioning by Integrating Target Information through a Heterogeneous Network Model. Bioinformatics Advance Access. 2014;30:1-18.
22. Zhong F, Xing J, Li X, Liu X, Fu Z, Xiong Z, et al. Artificial intelligence in drug design. Science China Life Science. 2018;61(10):1191-204.
23. Cukuroglu E, Engin HB, Gursoy A, Keskin O. Hot spots in protein-protein interfaces: towards drug discovery. Progress in Biophysics and Molecular Biology. 2014;116(2-3):165-73.
24. Higueruelo AP, Jubb H, Blundell TL. Protein-protein interactions as druggable targets: recent technological advances. Current Opinion in Pharmacology. 2013;13(5):791-6.
25. Lusci A, Pollastri G, Baldi P. Deep architectures and deep learning in chemoinformatics: the prediction of aqueous solubility for drug-like molecules. Journal of Chemical Information and Modeling. 2013;53(7):1563-75.
26. Reymond J-L, van Deursen R, Blum LC, Ruddigkeit L. Chemical space as a source for new drugs. MedChemComm. 2010;1(1):30-8.
27. Hartenfeller M, Schneider G. De novo drug design. Methods in Molecular Biology. 2011;672:299-323.
28. Schneider G, Funatsu K, Okuno Y, Winkler D. De novo Drug Design – Ye olde Scoring Problem Revisited. Molecular Informatic. 2017;36:1-2.
29. Lavecchia A, Giovanni CD. Virtual Screening Strategies in Drug Discovery: A Critical Review. Current Medicinal Chemistry. 2013;20(23):2839-60.
30. Huang SY, Grinter SZ, Zou X. Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys Chem Chem Phys. 2010;12(40):12899-908.
31. Khamis MA, Gomaa W, Ahmed WF. Machine learning in computational docking. Artificial Intelligence In Medicine. 2015;63(3):1-55.
32. Esposito EX, Hopfinger AJ, Madura JD. Methods for Applying the Quantitative Structure–Activity Relationship Paradigm. Chemoinformatics. 2004;275:131-213.
33. Myint KZ, Xie XQ. Recent advances in fragment-based QSAR and multi-dimensional QSAR methods. nternational Journal of Molecular Sciences. 2010;11(10):3846-66.
34. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nature Medicine. 2017;23(4):405-8.
35. LotfiShahreza M, Ghadiri N, Mousavi SR, Varshosaz J, Green JR. A review of network-based approaches to drug repositioning. Brief Bioinform. 2018;19(5):878-92.
36. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: Toxicity Prediction using Deep Learning. Frontiers in Environmental Science. 2016;3:1-15.
37. Bain EE, Shafner L, Walling DP, Othman AA, Chuang-Stein C, Hinkle J, et al. Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR Publications. 2017;5(2):1-14.
38. Deliberato RO, Celi LA, Stone DJ. Clinical Note Creation, Binning, and Artificial Intelligence. JMIR Publications. 2017;5(3):1-11.
39. Reddy AS, Zhang S. Polypharmacology: drug discovery for the future. Expert Reviews Clinical Pharmacology. 2013;6(1):41-7.
40. Thaliyachira C. First AI-Created Drug Enters Human Clinical Trial. OMR Industry Journal. 2020.

Published

2021-10-15

How to Cite

Mishra, D. K., & Awasthi, H. (2021). Artificial Intelligence: A New Era in Drug Discovery. Asian Journal of Pharmaceutical Research and Development, 9(5), 87–92. https://doi.org/10.22270/ajprd.v9i5.995

Issue

Vol. 9 No. 5 (2021): Vol 9 No 5 (2021): Vol 9 No 5 (2021): Volume 9 Issue 5 Set. - Oct. 2021

Section

Review Articles

AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).